SEC Form 4 · accession 0001140361-16-065832
Corvus Pharmaceuticals, Inc. · CRVS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard A Miller M.D.
Officer — President and CEO · Director
Period of report
May 12, 2016
Accepted (ET)
May 16, 2016 · 6:38 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001626971
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par valueF1 | May 12, 2016 | P | 30,000 | $10.00 | A | 1,076,993 | I | By Trust |
| Common Stock, $0.0001 par valueF2,F1 | May 13, 2016 | P | 300 | $9.9367 | A | 1,077,293 | I | By Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These shares are held by Richard A. Miller and Sandra J. Horning, Trustees of the Miller-Horning Family Trust u/a/d January 25, 1985 (the "Miller-Horning Trust"). Dr. Miller has shared voting, investment and dispositive power over the shares held by the Miller-Horning Trust.
- F2This transaction was executed in multiple trades in prices ranging from $9.905 to $10.00, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote.